Ignite Creation Date:
2024-05-05 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00488345
Status:
COMPLETED
Last Update Posted:
2012-10-24
First Post:
2007-06-18
Brief Title:
Study Evaluating the Pharmacokinetics PK Safety and Tolerability of Tigecycline in Patients 8 to 11 Years of Age
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Open-Label Ascending Multiple-Dose Study to Assess the Pharmacokinetics Safety and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections
Status:
COMPLETED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections complicated intra-abdominal infections cIAI complicated skin and skin structure infections cSSSI or community-acquired pneumonia CAP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None